Modeling long QT syndromes using induced pluripotent stem cells: Current progress and future challenges

Trends in Cardiovascular Medicine

Volumn 23, Issue 4, 2013, Pages 91-98

  Friedrichs, Stephanie ^a   Malan, Daniela ^a   Sasse, Philipp ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPRENALINE; NADOLOL; NICORANDIL; POTASSIUM CHANNEL KCNQ1; PROPRANOLOL;

ACTION POTENTIAL; CARDIOVASCULAR MORTALITY; DEPOLARIZATION; ELECTRIC POTENTIAL; EMBRYONIC STEM CELL; FIBROBLAST; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; LONG QT SYNDROME 3; PATCH CLAMP; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; FORECASTING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; ION CHANNELS; LONG QT SYNDROME; MODELS, CARDIOVASCULAR; MUTATION; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES;

EID: 84875878666     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.09.006     Document Type: Review

References (46)

1. Anderson C.L., Delisle B.P., Anson B.D., Kilby J.A., Will M.L., Tester D.J., et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 2006, 113:365-373.
2. Bennett P.B., Yazawa K., Makita N., George A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376:683-685.
3. + channels expressed in mammalian cells. American Journal of Physiology 1998, 274:H1643-H1654.
4. Charpentier F., Bourge A., Merot J. Mouse models of SCN5A-related cardiac arrhythmias. Progress in Biophysics and Molecular Biology 2008, 98:230-237.
5. Clancy C.E., Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002, 105:1208-1213.
6. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125:3079-3091.
7. Egashira T., Yuasa S., Suzuki T., Aizawa Y., Yamakawa H., Matsuhashi T., et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovascular Research 2012, 95(4):419-429.
8. Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy Series B: Physical and Biological Sciences 2009, 85:348-362.
9. Gellens M.E., George A.L., Chen L.Q., Chahine M., Horn R., Barchi R.L., et al. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:554-558.
10. Gherghiceanu M., Barad L., Novak A., Reiter I., Itskovitz-Eldor J., Binah O., et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. Journal of Cellular and Molecular Medicine 2011, 15:2539-2551.
11. Gouas L., Bellocq C., Berthet M., Potet F., Demolombe S., Forhan A., et al. New KCNQ1 mutations leading to haploinsufficiency in a general population; Defective trafficking of a KvLQT1 mutant. Cardiovascular Research 2004, 63:60-68.
12. Halbach M., Egert U., Hescheler J., Banach K. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cellular Physiology and Biochemistry 2003, 13:271-284.
13. Hattori F., Chen H., Yamashita H., Tohyama S., Satoh Y.S., Yuasa S., et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nature Methods 2010, 7:61-66.
14. Hedley P.L., Jorgensen P., Schlamowitz S., Wangari R., Moolman-Smook J., Brink P.A., et al. The genetic basis of long QT and short QT syndromes: a mutation update. Human Mutation 2009, 30:1486-1511.
15. Huber I., Itzhaki I., Caspi O., Arbel G., Tzukerman M., Gepstein A., et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. The FASEB Journal 2007, 21:2551-2563.
16. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
17. Jiang J., Han P., Zhang Q., Zhao J., Ma Y., Mercola M. Cardiac differentiation of human pluripotent stem cells. Journal of Cellular and Molecular Medicine 2012, 16:1663-1668.
18. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
19. Kita-Matsuo H., Barcova M., Prigozhina N., Salomonis N., Wei K., Jacot J.G., et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One 2009, 4:e5046.
20. Kolossov E., Bostani T., Roell W., Breitbach M., Pillekamp F., Nygren J.M., et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. Journal of Experimental Medicine 2006, 203:2315-2327.
21. Kupershmidt S., Yang T., Anderson M.E., Wessels A., Niswender K.D., Magnuson M.A., et al. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circulation Research 1999, 84:146-152.
22. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Disease Models and Mechanisms 2012, 5:220-230.
23. Malan D., Friedrichs S., Fleischmann B.K., Sasse P. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circulation Research 2011, 109:841-847.
24. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal 2011, 32:952-962.
25. Mauritz C., Schwanke K., Reppel M., Neef S., Katsirntaki K., Maier L.S., et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008, 118:507-517.
26. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. New England Journal of Medicine 2010, 363:1397-1409.
27. Moss A.J., Schwartz P.J., Crampton R.S., Tzivoni D., Locati E.H., MacCluer J., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991, 84:1136-1144.
28. Moss A.J., Zareba W., Kaufman E.S., Gartman E., Peterson D.R., Benhorin J., et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002, 105:794-799.
29. Mummery C.L., Zhang J., Ng E.S., Elliott D.A., Elefanty A.G., Kamp T.J. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circulation Research 2012, 111:344-358.
30. Niebruegge S., Bauwens C.L., Peerani R., Thavandiran N., Masse S., Sevaptisidis E., et al. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnology and Bioengineering 2009, 102:493-507.
31. Nuyens D., Stengl M., Dugarmaa S., Rossenbacker T., Compernolle V., Rudy Y., et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nature Medicine 2001, 7:1021-1027.
32. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
33. Park K.H., Piron J., Dahimene S., Merot J., Baro I., Escande D., et al. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome. Circulation Research 2005, 96:730-739.
34. Priori S.G., Napolitano C., Schwartz P.J., Grillo M., Bloise R., Ronchetti E., et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA: The Journal of the American Medical Association 2004, 292:1341-1344.
35. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103:89-95.
36. Shalaby F.Y., Levesque P.C., Yang W.P., Little W.A., Conder M.L., Jenkins-West T., et al. Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96:1733-1736.
37. Stadtfeld M., Brennand K., Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Current Biology 2008, 18:890-894.
38. Stoelzle S., Obergrussberger A., Bruggemann A., Haarmann C., George M., Kettenhofen R., et al. State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening. Frontiers in Pharmacology 2011, 2:76.
39. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
40. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
41. Tavernier G., Wolfrum K., Demeester J., De Smedt S.C., Adjaye J., Rejman J. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. Biomaterials 2012, 33:412-417.
42. Ungrin M.D., Joshi C., Nica A., Bauwens C., Zandstra P.W. Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS One 2008, 3:e1565.
43. Varas F., Stadtfeld M., de Andres-Aguayo L., Maherali N., di T.A., Pantano L., et al. Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions. Stem Cells 2009, 27:300-306.
44. Wang Q., Curran M.E., Splawski I., Burn T.C., Millholland J.M., VanRaay T.J., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996, 12:17-23.
45. Xu X.Q., Soo S.Y., Sun W., Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009, 27:2163-2174.
46. Zhou Z., Gong Q., Epstein M.L., January C.T. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. Journal of Biological Chemistry 1998, 273:21061-21066.